Abstract
BackgroundInhibition of interleukin (IL)-1 represents a promising treatment option in adult-onset Still's disease (AOSD).ObjectiveTo investigate the efficacy and safety of canakinumab in patients with AOSD and active joint involvement by...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have